C3i is attending the 59th ASH Annual Meeting and Exposition next week!
C3i will attend the 59th ASH Annual Meeting and Exposition in Atlanta from December 9th to 12th to engage with researchers, clinicians and industry leaders in the Hematology field. François Bettez, our CEO as well as Dr Lambert Busque our CMO, and Dr Denis-Claude Roy ou CSO, will be representing and promoting C3i for its outstanding capacity to help biotech companies and pharmas to achieve their objectives.
C3i was on the ground at ISSCR 2026 in Montréal, where one message came through clearly: cell and gene therapy is moving from scientific promise to clinical and commercial reality. Academia and industry have taken meaningful steps forward this past year, and the momentum is building. A few takeaways stood out: Clinical progress is accelerating […]
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
